Distinguished in Heart Attack

Marc J. Claeys

Antwerpen, VLG, BE 
Distinguished in Heart Attack
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Marc Claeys practices in Antwerpen, Belgium. Mr. Claeys is rated as a Distinguished expert by MediFind in the treatment of Heart Attack. His top areas of expertise are Heart Attack, Acute Coronary Syndrome, Unstable Angina, Percutaneous Coronary Intervention (PCI), and Thrombectomy.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 56 articles and participated in 1 clinical trial in the study of Heart Attack.

Gender
Male

Locations

Antwerpen, VLG, Belgium
Other Locations
Edegem, VLG, Belgium
VUB
Brussels, BRU, Belgium
Rue Wayez 35, 1420, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction: A Multicenter, Randomized, Controlled Clinical Trial (CARIOCA Study)
Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction: A Multicenter, Randomized, Controlled Clinical Trial (CARIOCA Study)
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Phase: Phase 3
Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of In-stent Restenosis After Percutaneous Coronary Intervention.
Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of In-stent Restenosis After Percutaneous Coronary Intervention.
Enrollment Status: Completed
Publish Date: November 04, 2022
View 2 Less Clinical Trials

131 Total Publications

Summary of 2021 ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy, on cardiovascular disease prevention, on the management of valvular heart disease and of heart failure.
Summary of 2021 ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy, on cardiovascular disease prevention, on the management of valvular heart disease and of heart failure.
Journal: Acta cardiologica
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Claeys's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile